Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Net Cash Flow: 2015-2025

Historic Net Cash Flow for Cartesian Therapeutics (RNAC) over the last 10 years, with Sep 2025 value amounting to -$16.9 million.

  • Cartesian Therapeutics' Net Cash Flow fell 112.83% to -$16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.8 million, marking a year-over-year decrease of 154.17%. This contributed to the annual value of $136.0 million for FY2024, which is 558.00% up from last year.
  • Cartesian Therapeutics' Net Cash Flow amounted to -$16.9 million in Q3 2025, which was up 15.59% from -$20.1 million recorded in Q2 2025.
  • Cartesian Therapeutics' 5-year Net Cash Flow high stood at $132.0 million for Q3 2024, and its period low was -$34.0 million during Q3 2023.
  • Over the past 3 years, Cartesian Therapeutics' median Net Cash Flow value was -$12.5 million (recorded in 2023), while the average stood at $3.4 million.
  • Examining YoY changes over the last 5 years, Cartesian Therapeutics' Net Cash Flow showed a top increase of 7,416.87% in 2022 and a maximum decrease of 992.78% in 2022.
  • Quarterly analysis of 5 years shows Cartesian Therapeutics' Net Cash Flow stood at -$582,000 in 2021, then crashed by 992.78% to -$6.4 million in 2022, then surged by 57.42% to -$2.7 million in 2023, then plummeted by 142.73% to -$6.6 million in 2024, then crashed by 112.83% to -$16.9 million in 2025.
  • Its last three reported values are -$16.9 million in Q3 2025, -$20.1 million for Q2 2025, and -$32.2 million during Q1 2025.